Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2020)
ALK-positive anaplastic large cell lymphomaDefinitions
J. Fromm, J. McEarchern, D. Kennedy, Anju Thomas, A. Shustov, A. Gopal (2012)
Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms.Clinical lymphoma, myeloma & leukemia, 12 4
(2017)
Primary cutaneous CD30positive T-cell lymphoproliferative disorders
Robert Chen, Jessie Hou, E. Newman, Young Kim, C. Donohue, Xueli Liu, Sandra Thomas, S. Forman, S. Kane (2015)
CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab VedotinMolecular Cancer Therapeutics, 14
H Arai, S Furuichi, Y Nakamura (2016)
ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotinRinsho Ketsuiki, 57
P. Gaulard, L. Leval (2016)
ALK-negative anaplastic large-cell lymphoma.Blood, 127 2
R Willemze, M Pauli, ME Kadin (2017)
WHO classification of tumours of haematopoietic and lymphoid tissues, revised
M Onciu, FG Behn, SC Raimondi (2003)
ALK-positive anaplastic large cell lymphoma with leukemic peripheral blood involvement is a clinipathologic entity with an unfavorable prognosisAJCP, 120
R. Al-Rohil, C. Torres‐Cabala, A. Patel, M. Tetzlaff, D. Ivan, P. Nagarajan, J. Curry, R. Miranda, M. Duvic, V. Prieto, P. Aung (2016)
Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel findingJournal of Cutaneous Pathology, 43
J. Juco, J. Holden, K. Mann, Lloyd Kelley, Shiyong Li (2003)
Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry.American journal of clinical pathology, 119 2
C. Nielson, R. Fischer, G. Fraga, D. Aires (2016)
Loss of CD30 Expression in Anaplastic Large Cell Lymphoma Following Brentuximab Therapy.Journal of drugs in dermatology : JDD, 15 7
Ying Lu, Xiaohui Zhao, Endi Wang, Wei Chen, Qin Huang (2010)
ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase".Leukemia research, 34 4
Leukemic phase of anaplastic large cell lymphoma (ALCL) is extremely rare. We present a case of primary cutaneous-ALCL (C-ALCL), who developed nodal involvement 4 years later. The patient was treated with combination chemotherapy and autologous stem cell transplantation; however, she relapsed 5 months later. At that time, the patient was given brentuximab vedotin (BV) with initial response. One year later, the patient demonstrated progressive adenopathy and leukemic involvement by her ALCL (comparative T cell clonality showed PCR products of the same size in the diagnostic skin and relapsed leukemic blood). Interestingly, the circulating tumor cells showed only subset expression of CD30 by flow cytometry (performed on peripheral blood). This patient demonstrates an unusual manifestation of ALCL (leukemic phase), with the additional confounder of CD30 downregulation, perhaps secondary to the BV therapy, or possible CD30-negative tumor escape.
Journal of Hematopathology – Springer Journals
Published: Mar 2, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.